Illumina Oncology - Testing for 𝘕𝘛𝘙𝘒 fusions

14 November 2022

Vivek Subbiah, MD, explains how patients with rare and common tumors can benefit from next generation sequencing-based testing for _NTRK_ gene fusions. He presents the case of a patient who benefited from precision medicine based on the detection of a _NTRK1_ fusion by comprehensive genomic profiling. Vivek Subbiah, MD is the Medical Director of the Clinical Center for Targeted Therapy and Executive Director of Oncology Research at the University of Texas MD Anderson Cancer Network. Listen to the podcast episode to learn more about when to test for _NTRK_ fusions: https://www.illumina.com/science/genomics-podcast/testing-for-ntrk-fusions.html Learn about Homologous Recombination Deficiency (HRD) testing in ovarian cancer: https://youtu.be/54yI7Sxvnfc The Illumina Oncology series is brought to you by Medical Affairs. M-GL-01113 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

Share this article on